tbuckley/cabot-search huggingface dataset:
HSR23-108: Physician Preferences on Biomarker Testing in Newly-Diagnosed Metastatic NSCLC Patients Who Had Insufficient Tumor Tissue
Authors: Anne Shah, Jon Apple, Gabriela Burgos, Josh Lankin, Jesse Cohn, Janelle Cambron-Mellott, Emily Mulvihill
Journal: Journal of the National Comprehensive Cancer Network (2023)

"HSR23-108: Physician Preferences on Biomarker Testing in Newly-Diagnosed Metastatic NSCLC Patients Who Had Insufficient Tumor Tissue" published on 31 Mar 2023 by National Comprehensive Cancer Network.
CLO23-045: A Prospective Interventional Study to Assess the Response of Systemic Chemotherapy in Aggressive, Recurrent Giant Cell Tumor
Authors: Saroj Sah, Mohit Dhingra, Amit Sehrawat, Sonal Saran
Journal: Journal of the National Comprehensive Cancer Network (2023)

"CLO23-045: A Prospective Interventional Study to Assess the Response of Systemic Chemotherapy in Aggressive, Recurrent Giant Cell Tumor" published on 31 Mar 2023 by National Comprehensive Cancer Network.
CGE23-073: Tissue and Liquid Biopsy Utilization in Advanced NSCLC in a Large Community US Practice
Authors: Alison Roos, Lucio Gordan, Michael Diaz, Anjan Patel, Matthew Fink, David Wenk, John Jiang, Janice Tam, Pratheesh Sathyan, Phil Febbo
Journal: Journal of the National Comprehensive Cancer Network (2023)
Cognitive Behavioral Therapy for Late-Life Depression (CBTlate): Results of a Multicenter, Randomized, Observer-Blinded, Controlled Trial
Authors: Forugh S. Dafsari, Bettina Bewernick, Sabine Böhringer, Katharina Domschke, Moritz Elsaesser, Margrit Löbner, Melanie Luppa, Lukas Preis, Julia Püsken, Sandra Schmitt, Andreea-Johanna Szekely, Martin Hellmich, Wiebke Müller, Michael Wagner, Oliver Peters, Lutz Frölich, Steffi Riedel-Heller, Elisabeth Schramm, Martin Hautzinger, Frank Jessen
Journal: Psychotherapy and Psychosomatics (2023)

Introduction: Different psychotherapeutic interventions for late-life depression (LLD) have been proposed, but their evaluation in large, multicenter trials is rare. Objective: The present study evaluated the efficacy of a specific cognitive behavioral therapy (CBT) for LLD (LLD-CBT) in comparison with a supportive unspecific intervention (SUI), both administered in a specialist psychiatric outpatient setting. Methods: In this randomized, controlled, parallel group trial, we recruited participants (≥60 years) with moderate to severe depression at 7 trial sites in Germany. Participants were randomly assigned to the LLD-CBT or SUI group. The primary outcome was depression severity at the end of treatment measured by change on the Geriatric Depression Scale (GDS). Secondary outcomes included change in observer-rated depression, anxiety, sleep ratings, and quality of life throughout the treatment phase and at 6-month follow-up. Results: Between October 1, 2018, and November 11, 2020, we randomly assigned 251 patients to either LLD-CBT (n = 126) or SUI (n = 125), of whom 229 provided primary-outcome data. There was no significant between-group difference in the change in GDS scores at the end of treatment (estimated marginal mean difference: −1.01 [95% CI: −2.88 to 0.86]; p = 0.287). Secondary analyses showed significant improvements in several outcomes after 8 weeks and at follow-up in both treatment arms. Conclusions: Our data suggest that LLD-specific CBT and a supportive unspecific treatment both provide clinical benefit in patients with moderate to severe LLD without evidence for superiority of LLD-CBT.
Causes, Consequences, and Treatments of Sleep and Circadian Disruption in the ICU: An Official American Thoracic Society Research Statement
Authors: Melissa P. Knauert, Najib T. Ayas, Karen J. Bosma, Xavier Drouot, Mojdeh S. Heavner, Robert L. Owens, Paula L. Watson, M. Elizabeth Wilcox, Brian J. Anderson, Makayla L. Cordoza, John W. Devlin, Rosalind Elliott, Brian K. Gehlbach, Timothy D. Girard, Biren B. Kamdar, Amy S. Korwin, Elizabeth R. Lusczek, Sairam Parthasarathy, Claudia Spies, Jag Sunderram, Irene Telias, Gerald L. Weinhouse, Phyllis C. Zee
Journal: American Journal of Respiratory and Critical Care Medicine (2023)

Section:ChooseTop of pageAbstract <<OverviewIntroductionSleep, Circadian Rhythms,...MethodsDefinitionsSubtopic 1: Prevalence, I...Subtopic 2: Measurement o...Subtopic 3: Outcomes of I...Subtopic 4: Treatment of ...ConclusionsReferences
CLO23-056: Risk of Second Malignancy Among Non-Metastatic Seminoma Patients Treated With Radiation Therapy and Chemotherapy in Manitoba
Authors: Vibhay Pareek, Marina Adu-Quaye, Justin Owen, Oliver Bucher, Aldrich Ong, Arbind Dubey, Bashir Bashir, Rashmi Koul
Journal: Journal of the National Comprehensive Cancer Network (2023)

"CLO23-056: Risk of Second Malignancy Among Non-Metastatic Seminoma Patients Treated With Radiation Therapy and Chemotherapy in Manitoba" published on 31 Mar 2023 by National Comprehensive Cancer Network.
CLO23-039: Safety Profile of Sonic Hedgehog Inhibitors in Basal Cell Carcinoma: A Systematic Review
Authors: Muhammad Zain Farooq, Mishal Shan Siddiqui, Syed Ali Farhan, Mahima Khatri, Syed Hamza Bin Waqar, Saad Khalid, Ankit Mangla
Journal: Journal of the National Comprehensive Cancer Network (2023)
HSR23-097: Health-Related Quality of Life in Patients With Metastatic Basal Cell Carcinoma Treated With Cemiplimab: Analysis of a Phase 2 Open-Label Clinical Trial
Authors: Karl D. Lewis, Timothy J. Inocencio, Ruben G.W. Quek, Patrick R. LaFontaine, Zeynep Eroglu, Anne Lynn S. Chang, Cristina Ivanescu, Alexander J. Stratigos, Ketty Peris, Aleksandar Sekulic, Matthew G. Fury, Chieh-I Chen
Journal: Journal of the National Comprehensive Cancer Network (2023)

"HSR23-097: Health-Related Quality of Life in Patients With Metastatic Basal Cell Carcinoma Treated With Cemiplimab: Analysis of a Phase 2 Open-Label Clinical Trial" published on 31 Mar 2023 by National Comprehensive Cancer Network.
CLO23-066: Risk of Secondary Malignancies After Platinum-Based Chemotherapy in Testicular Seminoma Patients: A Population-Based Study
Authors: Hiffsa Taj, Ayman Qasrawi, Zin Myint
Journal: Journal of the National Comprehensive Cancer Network (2023)

"CLO23-066: Risk of Secondary Malignancies After Platinum-Based Chemotherapy in Testicular Seminoma Patients: A Population-Based Study" published on 31 Mar 2023 by National Comprehensive Cancer Network.
CLO23-027: Do Proton Pump Inhibitors Affect the Effectiveness of Capecitabine-Based Chemotherapy in Colorectal Cancers? A Systematic Review With Meta-Analysis
Authors: Chin-Hsuan Huang, Andrea S Porpiglia, Yi-No Kang, Yu Chang, Kuan-Yu Chi
Journal: Journal of the National Comprehensive Cancer Network (2023)

"CLO23-027: Do Proton Pump Inhibitors Affect the Effectiveness of Capecitabine-Based Chemotherapy in Colorectal Cancers? A Systematic Review With Meta-Analysis" published on 31 Mar 2023 by National Comprehensive Cancer Network.
CLO23-057: The Influence of Operability Status on Outcomes in Patients With T4a Larynx Cancer: An Institutional Experience
Authors: Ashley Schlafstein, Subir Goyal, Ashley Aiken, Jill Remick, Nabil Saba, James Bates, Soumon Rudra, Mark McDonald, Azeem Kaka, William Stokes
Journal: Journal of the National Comprehensive Cancer Network (2023)
CGE23-072: The Frequency of Androgen Receptor Splice Variant 7 (AR-V7) in Solid Tumors
Authors: Zoran Gatalica, Jess Hoag, David W Hall, Fadel S Alyaqoub, Susan Dombrowski, Pawan Noel, Szabolcs Szelinger, Sameer Udhane, Wang Min, Snehal G Thakkar, Gargi Basu
Journal: Journal of the National Comprehensive Cancer Network (2023)
CLO23-024: Evaluating the Clinical Significance of Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Patients With Non–Small Cell Lung Cancer (NSCLC)
Authors: Mason Alford, Candace J. Grisham, Christopher Thompson, Wade T. Iams
Journal: Journal of the National Comprehensive Cancer Network (2023)

"CLO23-024: Evaluating the Clinical Significance of Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Patients With Non–Small Cell Lung Cancer (NSCLC)" published on 31 Mar 2023 by National Comprehensive Cancer Network.
CLO23-048: Disparities in Outcomes of Chemotherapy-Related Febrile Neutropenia Patients: A Nationwide Study of Hospitalizations
Authors: Akhil Jain, Sohiel Deshpande, Krishna Desai, Sabah Iqbal, Aisha Sultan, Monika Garg, Bohdan Baralo, Rajesh Thirumaran
Journal: Journal of the National Comprehensive Cancer Network (2023)
Longitudinal Fecal Calprotectin Profiles Characterize Disease Course Heterogeneity in Crohn’s Disease
Authors: Nathan Constantine-Cooke, Karla Monterrubio-Gómez, Nikolas Plevris, Lauranne A.A.P. Derikx, Beatriz Gros, Gareth-Rhys Jones, Riccardo E. Marioni, Charlie W. Lees, Catalina A. Vallejos
Journal: Clinical Gastroenterology and Hepatology (2023)

The progressive nature of Crohn's disease is highly variable and hard to predict. In addition, symptoms correlate poorly with mucosal inflammation. There is therefore an urgent need to better characterize the heterogeneity of disease trajectories in Crohn's disease by utilizing objective markers of inflammation. We aimed to better understand this heterogeneity by clustering Crohn's disease patients with similar longitudinal fecal calprotectin profiles.We performed a retrospective cohort study at the Edinburgh IBD Unit, a tertiary referral center, and used latent class mixed models to cluster Crohn's disease subjects using fecal calprotectin observed within 5 years of diagnosis. Information criteria, alluvial plots, and cluster trajectories were used to decide the optimal number of clusters. Chi-square test, Fisher's exact test, and analysis of variance were used to test for associations with variables commonly assessed at diagnosis.Our study cohort comprised 356 patients with newly diagnosed Crohn's disease and 2856 fecal calprotectin measurements taken within 5 years of diagnosis (median 7 per subject). Four distinct clusters were identified by characteristic calprotectin profiles: a cluster with consistently high fecal calprotectin and 3 clusters characterized by different downward longitudinal trends. Cluster membership was significantly associated with smoking (P = .015), upper gastrointestinal involvement (P < .001), and early biologic therapy (P < .001).Our analysis demonstrates a novel approach to characterizing the heterogeneity of Crohn's disease by using fecal calprotectin. The group profiles do not simply reflect different treatment regimens and do not mirror classical disease progression endpoints.
HSR23-102: Diagnosis of Metastatic Non–Small Cell Lung Cancer During Hospitalization: Missed Opportunity for Optimal Supportive Care?
Authors: Shristi Upadhyay Banskota, Conor Houlihan, Jonathan Q. Trinh, Samia Asif, Omar Abughanimeh, Benjamin A. Teply
Journal: Journal of the National Comprehensive Cancer Network (2023)

"HSR23-102: Diagnosis of Metastatic Non–Small Cell Lung Cancer During Hospitalization: Missed Opportunity for Optimal Supportive Care?" published on 31 Mar 2023 by National Comprehensive Cancer Network.
CLO23-059: HDR-ICR Brachytherapy With Solo Anesthesia Administration as a Resource-Effective and Patient-Safe Method in Cancer Cervix
Authors: Salwa Fathy, Umm Salma Mohamamed, Mazen Al-Gaoud, Nasser Al-Dhaibani, Maha Alidrisi
Journal: Journal of the National Comprehensive Cancer Network (2023)

"CLO23-059: HDR-ICR Brachytherapy With Solo Anesthesia Administration as a Resource-Effective and Patient-Safe Method in Cancer Cervix" published on 31 Mar 2023 by National Comprehensive Cancer Network.
CLO23-068: Effectiveness and Toxicity of Cetuximab With Concurrent Radiotherapy in Locally Advanced Cutaneous Squamous Cell Skin Cancer: A Case Series
Authors: Mark Joshua Chang, Wolfram Samlowski, Douglas Fife, Mac Machan, Raul Meoz
Journal: Journal of the National Comprehensive Cancer Network (2023)

"CLO23-068: Effectiveness and Toxicity of Cetuximab With Concurrent Radiotherapy in Locally Advanced Cutaneous Squamous Cell Skin Cancer: A Case Series" published on 31 Mar 2023 by National Comprehensive Cancer Network.
CLO23-067: Race and Gender Specific Trends of Mortality From Hepatocellular Carcinoma in the United States, 1999–2020
Authors: Abdul Rahman Al Armashi, Anas Al Zubaidi, Apoorva Krishna Chandar, Dina Elantably, Faris Hammad, Kanchi Patell, Mohamed Homeida, Akram Alkrekshi
Journal: Journal of the National Comprehensive Cancer Network (2023)
CLO23-055: Does Anemia Contribute to Increased Risk of Adverse Outcomes in Cancer Patients With Venous Thromboembolism? A Longitudinal Study From National Representative Population
Authors: Akhil Jain, Sohiel Deshpande, Sabah Iqbal, Krishna Desai, Aisha Sultana, Kristal Pereria, Aisha Abdul Sattar, Mohammad Hamza, Bohdan Baralo, Rajesh Thirumaran
Journal: Journal of the National Comprehensive Cancer Network (2023)

"CLO23-055: Does Anemia Contribute to Increased Risk of Adverse Outcomes in Cancer Patients With Venous Thromboembolism? A Longitudinal Study From National Representative Population" published on 31 Mar 2023 by National Comprehensive Cancer Network.
CLO23-065: Dosimetric Comparison of Hypofractionation With Concomitant Boost Versus Sequential Boost Following Breast-Conserving Surgery in Early Stage Breast Cancer Patients
Authors: Joy Ogunmuyiwa, Hanaan Habibulla, Haoyu Wang, Onyinye Balogun, Hani Ashamalla
Journal: Journal of the National Comprehensive Cancer Network (2023)

"CLO23-065: Dosimetric Comparison of Hypofractionation With Concomitant Boost Versus Sequential Boost Following Breast-Conserving Surgery in Early Stage Breast Cancer Patients" published on 31 Mar 2023 by National Comprehensive Cancer Network.
Palliative care can benefit people with dementia
Authors: Emel Yorganci, Katherine E Sleeman
Journal: BMJ (2023)

Dementia is a life limiting, neurodegenerative condition that can be described as mental decline caused by many possible underlying diseases, including Alzheimer's.The Office for National Statistics reports that dementia was the leading cause of death in England in December 2022. 1 2 What is more, the number of people dying with dementia is projected to more than double by 2040 in England and Wales as a consequence of ageing populations. 3 However, public awareness of the life limiting nature of dementia is poor.A recent opinion poll 4 conducted with a representative sample of more than 2000 people in the UK found that just 42% were aware that dementia is a terminal condition, and over 90% didn't know that dementia is the leading cause of death in England.
BPI23-009: Oncologists’ Perceptions of a Novel Superoxide Dismutase Mimetic (Avasopasem Manganese) for Treating Severe Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer
Authors: Alexandrina Balanean, Brooke Leon, Yolaine Jeune-Smith, Chukwuemeka Ikpeazu, Bruce Feinberg
Journal: Journal of the National Comprehensive Cancer Network (2023)

"BPI23-009: Oncologists’ Perceptions of a Novel Superoxide Dismutase Mimetic (Avasopasem Manganese) for Treating Severe Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer" published on 31 Mar 2023 by National Comprehensive Cancer Network.
EPR23-086: Knowing the Lymphomas of the Legal Amazon: How Do They Differ?
Authors: Isadora Alves Praxedes, Cinthya Oliveira Nascimento, Iane da Costa Scharff, Alexandre Carvalho Garcia, Iara da Costa Scharff, Guilherme Eler de Almeida, João Guilherme Ruiz Ferreira
Journal: Journal of the National Comprehensive Cancer Network (2023)
BPI23-015: Frequency of Hereditary Cancer Syndromes in Pediatric Patients: Experience in a Tertiary Care Children’s Hospital in Mexico
Authors: Ana Carolina Tamayo Palacio, Alejandra del Pilar Reyes de la Rosa, Romina Viveros Rodriguez, Rodrigo Moreno Salgado
Journal: Journal of the National Comprehensive Cancer Network (2023)

"BPI23-015: Frequency of Hereditary Cancer Syndromes in Pediatric Patients: Experience in a Tertiary Care Children’s Hospital in Mexico" published on 31 Mar 2023 by National Comprehensive Cancer Network.
Association Between the Presence of Metabolic Comorbidities and Liver-Related Events in Patients With Chronic Hepatitis B
Authors: Lesley A. Patmore, Warshan K. Katwaroe, Daniel van der Spek, Hannah S.J. Choi, Keyur Patel, Sylvia Brakenhoff, Adriaan J. van der Meer, Willem P. Brouwer, Laurens A. van Kleef, Rob J. de Knegt, Bettina E. Hansen, Rob A. de Man, Jordan J. Feld, Harry L.A. Janssen, Milan J. Sonneveld
Journal: Clinical Gastroenterology and Hepatology (2023)

Patients with chronic hepatitis B (CHB) are at increased risk of hepatocellular carcinoma and (liver-related) mortality. In addition to hepatitis B-related factors, metabolic comorbidities may contribute to the progression of fibrosis. Therefore, we studied the association between metabolic comorbidities and adverse clinical outcomes in patients with CHB.We conducted a retrospective cohort study of CHB patients attending the Erasmus MC University Medical Center (Rotterdam, The Netherlands) and CHB patients who underwent liver biopsy at the Toronto General Hospital (Toronto, Canada). The presence of metabolic comorbidities (ie, overweight, diabetes mellitus, hypertension, and dyslipidemia) was assessed based on chart review. The primary end point was liver-related events, defined as the first composite of hepatocellular carcinoma, liver transplantation, or liver-related mortality.We analyzed 1850 patients, of whom 926 (50.1%) were overweight, 161 (8.7%) had hypertension, 116 (6.3%) had dyslipidemia, and 82 (4.4%) had diabetes. During a median follow-up period of 7.3 years (interquartile range, 2.9-11.5 y), a total of 111 first events were recorded. Hypertension (hazard ratio [HR], 8.3; 95% CI, 5.5-12.7), diabetes (HR, 5.4; 95% CI, 3.2-9.1), dyslipidemia (HR, 2.8; 95% CI, 1.6-4.8), and overweight (HR, 1.7; 95% CI, 1.1-2.5) were associated with an increased risk for liver-related events. The presence of multiple comorbidities further increased the risk. Findings were consistent for patients with and without cirrhosis, among noncirrhotic hepatitis B e antigen-negative patients with hepatitis B virus DNA less than 2000 IU/mL and in multivariable analysis adjusting for age, sex, ethnicity, hepatitis B e antigen status, hepatitis B virus DNA, use of antiviral therapy, and the presence of cirrhosis.Metabolic comorbidities in CHB patients are associated with an increased risk for liver-related events, with the highest risk observed in patients with multiple comorbidities. Findings were consistent in various clinically relevant subgroups, underscoring the need for thorough metabolic assessment in patients with CHB.
Retraction Notice to: Neural Stem Cells Engineered to Express Three Therapeutic Factors Mediate Recovery from Chronic Stage CNS Autoimmunity
Authors: Xing Li, Yuan Zhang, Yaping Yan, Bogoljub Ciric, Cun-Gen Ma, Bruno Gran, Mark Curtis, Abdolmohamad Rostami, Guang-Xian Zhang
Journal: Molecular Therapy (2023)

(Molecular Therapy 24, 1456–1469; August 2016) This article has been retracted at the request of the editor-in-chief. Similarities were found between images in this article and a previously published article in Scientific Reports (Zhang et al., 2015, Sci. Rep. 30, 17407, https://doi.org/10.1038/srep17407). Similarities were also found between images within this article. These concerns were initially reported in a PubPeer thread (https://pubpeer.com/publications/11D757FEEACDC81ACAF60BD0A32607). Image analysis performed by the editorial office confirmed findings of image reuse in Figures 2C and 5C of the Molecular Therapy article. In addition, some of the original data provided by the authors do not match the published article. This reuse (and in part misrepresentation) of data without appropriate attribution represents a severe abuse of the scientific publishing system. The authors disagree with this retraction and maintain that these mistakes do not alter the conclusions of the study. RETRACTED: Neural Stem Cells Engineered to Express Three Therapeutic Factors Mediate Recovery from Chronic Stage CNS AutoimmunityLi et al.Molecular TherapyAugust, 2016In BriefThis article has been retracted: please see Elsevier Policy on Article Withdrawal ( http://www.elsevier.com/locate/withdrawalpolicy ). Full-Text PDF Open Access
Effectiveness of Hepatitis B Vaccination for Patients With Inflammatory Bowel and Celiac Disease
Authors: Jessica A. Ulrich, Nawras W. Habash, Yasmine A. Ismail, William J. Tremaine, Amy L. Weaver, Joseph A. Murray, Edward V. Loftus, Imad Absah
Journal: Clinical Gastroenterology and Hepatology (2023)
NK-like CD8 <sup>+</sup> γδ T cells are expanded in persistent <i>Mycobacterium tuberculosis</i> infection
Authors: Roshni Roy Chowdhury, John R. Valainis, Megha Dubey, Lotta von Boehmer, Elsa Sola, Julie Wilhelmy, Jing Guo, Oliver Kask, Mane Ohanyan, Meng Sun, Huang Huang, Xianxi Huang, Patricia K. Nguyen, Thomas J. Scriba, Mark M. Davis, Sean C. Bendall, Yueh-hsiu Chien
Journal: Science Immunology (2023)

The response of gamma delta (γδ) T cells in the acute versus chronic phases of the same infection is unclear. How γδ T cells function in acute Mycobacterium tuberculosis (Mtb) infection is well characterized, but their response during persistent Mtb infection is not well understood, even though most infections with Mtb manifest as a chronic, clinically asymptomatic state. Here, we analyze peripheral blood γδ T cells from a South African adolescent cohort and show that a unique CD8 + γδ T cell subset with features of “memory inflation” expands in chronic Mtb infection. These cells are hyporesponsive to T cell receptor (TCR)–mediated signaling but, like NK cells, can mount robust CD16-mediated cytotoxic responses. These CD8 + γδ T cells comprise a highly focused TCR repertoire, with clonotypes that are Mycobacterium specific but not phosphoantigen reactive. Using multiparametric single-cell pseudo-time trajectory analysis, we identified the differentiation paths that these CD8 + γδ T cells follow to develop into effectors in this infection state. Last, we found that circulating CD8 + γδ T cells also expand in other chronic inflammatory conditions, including cardiovascular disease and cancer, suggesting that persistent antigenic exposure may drive similar γδ T cell effector programs and differentiation fates.
QIM23-132: Do EHR-Embedded Clinical Decision Support Tools Reduce Variation in Care? A Pre and Post-Implementation Comparison of Regimen Ordering Variation at a Multi-Site Community Cancer Clinic
Authors: Jonas M. Congelli, Heather Lewin, Gregory Calip, Marcello Ricottone, Shawn Huda, Taylor Dias-Foundas, Rebecca Maniago
Journal: Journal of the National Comprehensive Cancer Network (2023)

"QIM23-132: Do EHR-Embedded Clinical Decision Support Tools Reduce Variation in Care? A Pre and Post-Implementation Comparison of Regimen Ordering Variation at a Multi-Site Community Cancer Clinic" published on 31 Mar 2023 by National Comprehensive Cancer Network.
EPR23-082: Patient Awareness of Elevated Breast Cancer Risk After Routine Screening Mammogram and Risk Notification
Authors: Tasleem J Padamsee, Rachel Mason, Anna Muraveva, Wilson S Figueroa, Paige A. Swinehart-Hord, Steven Kalister, Sagar Sardesai, Bushra Siddiqi, Jeffrey Hawley, Clayton Taylor, Doreen Agnese, Hayley Cassingham, Kevin Sweet, Noel Huber, Heidi Basinger
Journal: Journal of the National Comprehensive Cancer Network (2023)
EPR23-084: Bimodal Distribution of Osteosarcoma: A Thing of the Past? Comparative Analysis From Surveillance, Epidemiology, and End Results (SEER) and National Inpatient Sample (NIS)
Authors: Emma Kar, Amrit Ammanamanchi, Arya Mishra, Jiali Ling, Bijun Kannadath
Journal: Journal of the National Comprehensive Cancer Network (2023)

"EPR23-084: Bimodal Distribution of Osteosarcoma: A Thing of the Past? Comparative Analysis From Surveillance, Epidemiology, and End Results (SEER) and National Inpatient Sample (NIS)" published on 31 Mar 2023 by National Comprehensive Cancer Network.
YIA23-003: CD19-CAR T Cells Develop Exhaustion Epigenetic Programs During a Clinical Response
Authors: Caitlin Zebley, Charmaine C Brown, Tian Mi, Yiping Fan, Shanta Alli, Shannon Boi, Giovanni Galletti, Enrico Lugli, Deanna Langfitt, Jean-Yves Metais, Timothy Lockey, Michael Meagher, Brandon Triplett, Aimee Talleur, Stephen Gottschalk, Ben Youngblood
Journal: Journal of the National Comprehensive Cancer Network (2023)